92 related articles for article (PubMed ID: 20554751)
1. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways.
Dasari A; Messersmith WA
Clin Cancer Res; 2010 Aug; 16(15):3811-8. PubMed ID: 20554751
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
3. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
Volante M; Saviozzi S; Rapa I; Ceppi P; Cappia S; Calogero R; Novello S; Borasio P; Papotti M; Scagliotti GV
Cancer; 2007 Sep; 110(6):1321-8. PubMed ID: 17647268
[TBL] [Abstract][Full Text] [Related]
5. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
6. Targeting signal transduction pathways in colorectal cancer--more than skin deep.
Cohen SJ; Cohen RB; Meropol NJ
J Clin Oncol; 2005 Aug; 23(23):5374-85. PubMed ID: 15998904
[TBL] [Abstract][Full Text] [Related]
7. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
Van Cutsem E
Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643
[TBL] [Abstract][Full Text] [Related]
8. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
[TBL] [Abstract][Full Text] [Related]
9. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
10. Targeting the EGFR and the PKB pathway in cancer.
Klein S; Levitzki A
Curr Opin Cell Biol; 2009 Apr; 21(2):185-93. PubMed ID: 19216065
[TBL] [Abstract][Full Text] [Related]
11. Targeted treatments in colorectal cancer: state of the art and future perspectives.
Arnold D; Seufferlein T
Gut; 2010 Jun; 59(6):838-58. PubMed ID: 20551469
[TBL] [Abstract][Full Text] [Related]
12. Responsiveness to cetuximab without mutations in EGFR.
Tsuchihashi Z; Khambata-Ford S; Hanna N; Jänne PA
N Engl J Med; 2005 Jul; 353(2):208-9. PubMed ID: 16014894
[No Abstract] [Full Text] [Related]
13. Development of molecular biomarkers in individualized treatment of colorectal cancer.
De Mattos-Arruda L; Dienstmann R; Tabernero J
Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies in the treatment of colorectal cancer.
Veronese ML; O'Dwyer PJ
Eur J Cancer; 2004 Jun; 40(9):1292-301. PubMed ID: 15177487
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.
Zwierzina H; Bardelli A; Ciardiello F; Gariboldi M; Håkansson L; Lambrechts D; Lind GE; Loeffler-Ragg J; Schmoll H; Siena S; Tabernero J; Van Cutsem E
Curr Opin Mol Ther; 2010 Dec; 12(6):703-11. PubMed ID: 21154162
[TBL] [Abstract][Full Text] [Related]
16. Novel targets for anticancer treatment development in colorectal cancer.
Macarulla T; Ramos FJ; Capdevila J; Saura C; Tabernero J
Clin Colorectal Cancer; 2006 Nov; 6(4):265-72. PubMed ID: 17241511
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for colorectal cancer resistance to EGF receptor antibodies and new trends.
Katsios C; Ziogas DE; Roukos DH; Baltogiannis G
Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):5-8. PubMed ID: 23265143
[No Abstract] [Full Text] [Related]
18. Integration of the anti-EGFR agent panitumumab into clinical practice in metastatic colorectal cancer.
Van Cutsem E
Clin Adv Hematol Oncol; 2007 Aug; 5(8):611-3. PubMed ID: 17982400
[No Abstract] [Full Text] [Related]
19. Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer.
Scartozzi M; Pierantoni C; Berardi R; Antognoli S; Bearzi I; Cascinu S
Anal Quant Cytol Histol; 2006 Apr; 28(2):61-8. PubMed ID: 16637508
[TBL] [Abstract][Full Text] [Related]
20. Consequences of feedback in signal transduction for targeted therapies.
Klinger B; Blüthgen N
Biochem Soc Trans; 2014 Aug; 42(4):770-5. PubMed ID: 25109956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
